The 2012 of the pharmaceutical company Sigma-Tau Finanziaria goes on file, closing with a return to net profit of 48,4 million euros, after the loss of 21,1 in 2011. This was communicated by the same company in a note . Although the economic situation remains difficult, it is explained, the growth in the United States and the good performance of nutracetes and drugs for rare diseases have allowed Sigma Tau to reach its targets.
The boost from foreign markets caused a 3,8% increase in net operating revenues, up to 688 million euro. The traditional business generated approximately 70 million euro of Ebitda against 50 in the previous year. The gross operating margin grew by 47% to 156,7 million, while the net financial position improved by approximately 120 million, settling at 140,3 million.
